NCT02463409View on ClinicalTrials.gov

Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Pseudohypoparathyroidism Type 1aAlbright Hereditary Osteodystrophy
Interventions
DRUG

Theophylline

24 hour infusion of IV theophylline

Trial Locations (1)

37232

Vanderbilt Unversity, Nashville

All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

lead

Vanderbilt University Medical Center

OTHER

NCT02463409 - Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy) | Biotech Hunter | Biotech Hunter